Complications of total implantable access ports and efficacy of Taurolidine-citrate lock solution against catheter-related infections.
BACKGROUND
Totally, implantable access ports (TIAPs) are used for long standing venous catheterization. This study was designed to present our experiences of the TIAPs applications and efficacy of Taurolidine-citrate lock solution (TCLS) against catheter-related infections.


METHODS
We evaluated records of the 108 patients implanted with 112 TIAPs, which had been performed using heparin solution or TCLS between 2005 and 2013.


RESULTS
Duration of exposure to TIAPs was 17-2051 days (median: 411 days). The primary diagnoses were solid tumours (n = 57), lymphoma (n = 23), haematologic diseases (n = 23), nephrotic syndrome (n = 4), Hirschsprung disease (n = 1). The right external jugular vein was most frequently used vascular access route (72.3%). Mechanical complications were observed in four cases. TIAPs were removed due to remission in 19 cases and infection in 19 cases. Median time from implantation and to the development of infection was 60 days. Heparin solution had been used for care in 33 ports, whereas heparin and TCLS had been used in 79 ports. Based on statistical comparison, use of TCLS was considered to be an important factor for preventing infection (P = 0.03).


CONCLUSIONS
We consider that TCLS reduces infection prevalence so TIAPs would be used more extensively and effectively to prevent infections.
Department of Paediatric Surgery, Başkent University, Faculty of Medicine, Ankara, Turkey.
Emine
E
Ince
Pelin
P
Oğuzkurt
Abdulkerim
A
Temiz
Semire Serin
SS
Ezer
Hasan Özkan
HÖ
Gezer
Nalan
N
Yazici
Akgün
A
Hiçsönmez
D000293:Adolescent; D055499:Catheter-Related Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D002405:Catheterization, Central Venous / Q000009:adverse effects* / Q000379:methods; D002408:Catheters, Indwelling / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D020878:Device Removal / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D012189:Retrospective Studies; D018570:Risk Assessment; D013654:Taurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013829:Thiadiazines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014421:Turkey
D013829:Thiadiazines; D013654:Taurine; C012566:taurolidine